Regeneron Pharmaceuticals (REGN) Cost of Revenue (2009 - 2026)

Regeneron Pharmaceuticals has reported Cost of Revenue for 18 years, with the latest figure at $296.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 48.89% year-over-year to $296.0 million; the trailing twelve-month figure through Mar 2026 stood at $950.0 million (down 5.97% YoY), and the FY2025 full-year result was $959.9 million, down 11.72% from the prior year.
• Cost of Revenue for Q1 2026 stood at $296.0 million, up from $137.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $326.8 million in Q4 2024, with the low at $137.8 million in Q4 2025.
• Average Cost of Revenue over 5 years is $224.0 million, with a median of $212.5 million recorded in 2023.
• Year-over-year, Cost of Revenue sank 70.63% in 2022 and soared 55.47% in 2024.
• Tracing REGN's Cost of Revenue over 5 years: stood at $238.4 million in 2022, then dropped by 11.83% to $210.2 million in 2023, then soared by 55.47% to $326.8 million in 2024, then slumped by 57.83% to $137.8 million in 2025, then jumped by 114.8% to $296.0 million in 2026.
• The last three Cost of Revenue figures came in at $296.0 million (Q1 2026), $137.8 million (Q4 2025), and $240.6 million (Q3 2025), per Business Quant data.

Peer Comparison